| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.300 | Biomarker | phenotype | CTD_human | Angiotensin II facilitates neointimal formation by increasing vascular smooth muscle cell migration: Involvement of APE/Ref-1-mediated overexpression of sphingosine-1-phosphate receptor 1. | 29609002 | 2018 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | These findings demonstrate that Ang II stimulates the epigenetic regulation of S1PR1 expression via H<sub>2</sub>O<sub>2</sub>-mediated APE/Ref-1 translocation, which may consequently be involved in Ang II-induced VSMC migration and vascular neointima formation. | 29609002 | 2018 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | Unexpected role of the copper transporter ATP7A in PDGF-induced vascular smooth muscle cell migration. | 20671235 | 2010 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | Cuff-induced vascular intima thickening is influenced by titration of the Ace gene in mice. | 19258495 | 2009 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2'-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). | 17964422 | 2007 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2'-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). | 17964422 | 2007 | ||||
|
0.300 | Biomarker | phenotype | CTD_human | Taken together, these results demonstrate that KLF5 plays an important role in the control of SMC phenotype after vascular injury and suggest the feasibility of using Am80, delivered systemically and/or with a drug eluting stent, to prevent in-stent neointima formation. | 16224062 | 2005 |